Literature DB >> 6125227

The Nithsdale Schizophrenia survey: II. Abnormal movements.

R G McCreadie, E T Barron, G S Winslow.   

Abstract

In a review of all known schizophrenics (n = 133) from a discrete geographical area, Nithsdale in Dumfries and Galloway Region, 88 per cent were examined for evidence of tardive dyskinesia (TD) and parkinsonism. The prevalence of both TD and parkinsonism was 31 per cent. The TD group was older and more often showed negative schizophrenic symptoms than the non-TD group. The trend was towards a higher prevalence among in-patients and Feighner positive schizophrenics. Parkinsonism was common in patients receiving anti-parkinsonian drugs. Ten per cent of patients had both TD and parkinsonism. The findings will act as a baseline for regular reassessment of the population.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6125227     DOI: 10.1192/bjp.140.6.587

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  4 in total

1.  Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.

Authors:  T M Hyde; M F Egan; L L Wing; R J Wyatt; D R Weinberger; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

2.  Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis.

Authors:  Jeroen P F Koning; Diederik E Tenback; Jim van Os; André Aleman; René S Kahn; Peter N van Harten
Journal:  Schizophr Bull       Date:  2008-11-05       Impact factor: 9.306

3.  The Nithsdale schizophrenia surveys. An overview.

Authors:  R G McCreadie
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1992-01       Impact factor: 4.328

4.  Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population.

Authors:  Sven Janno; Matti M Holi; Katinka Tuisku; Kristian Wahlbeck
Journal:  BMC Neurol       Date:  2005-03-17       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.